Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply

Rheumatology (Oxford). 2020 Sep 1;59(9):e48-e49. doi: 10.1093/rheumatology/keaa255.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Humans
  • Remission Induction
  • Takayasu Arteritis* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab